A Phase 1/2 interventional study of NS-050/NCNP-03 and Placebo in Duchenne Muscular Dystrophy, sponsored by NS Pharma, Inc.. Active, not recruiting at 19 sites in 5 countries. Open to male participants aged 4 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by NS Pharma, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. — 1 open to participants now, 5 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · NS Pharma, Inc..
Among the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., this one is one of 2 that started in 2024, is the only one in phase 1/2, and was the 9th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →1 of the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. is open now, in 7 countries. Recruiting first, the newest first:
NS Pharma, Inc. · Sites in United States, Australia, Canada and 4 more countries
Men only
By country, each count listing its studies:
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 15 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 2 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 20 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 20 across the 9 interventional studies. Of the 4 that completed or were terminated, 4 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
NS Pharma, Inc. is the lead sponsor of 16 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
1 of the studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05996003NS Pharma, Inc.NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | 2027-02-26 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other inclusion criteria may apply.
Exclusion Criteria:
Other exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized and receive NS-050/NCNP-03 intravenous (IV) infusions once weekly for 2 weeks at each of MAD levels (1.95, 5, 10, 20, 40, and 80 mg/kg).
Drug: NS-050/NCNP-03
Participants will be randomized and receive NS-050/NCNP-03 placebo-matching IV infusions once weekly for 2 weeks at each of MAD levels.
Drug: Placebo
Participants will receive NS-050/NCNP-03 IV infusions once weekly for 24 weeks at the dosage selected by the Data and Safety Monitoring Board (DSMB) at the conclusion of Part 1.
Drug: NS-050/NCNP-03
NS-050/NCNP-03 solution for IV infusion.
NS-050/NCNP-03 placebo-matching solution for IV infusion.
Part 1: Overall Summary of Treatment-emergent Adverse Events (TEAEs)
TEAEs will be summarized both at the patient level for number of TEAEs, highest severity, relationship, action, and outcome, and at the TEAE level (summarizing events) by system organ class (SOC) and preferred term (PT) as well as severity, relationship, action, and outcome. The most recent version of the Medical Dictionary for Regulatory Activities (MedDRA) will be used for coding TEAEs.
Time frame: Baseline up to Week 24
Part 1: Area Under the Plasma Concentration Versus Time Curve (AUC) of NS-050/NCNP-03
Blood samples will be collected at the designated time frame. Pharmacokinetic (PK) parameters of NS-050/NCNP-03 will be calculated using non-compartmental methods.
Time frame: Day 1 (1st dose) for each dose level
Part 1: Amount of Drug Excreted in Urine of NS-050/NCNP-03
Urine samples will be collected at the designated time frame. PK parameters of NS-050/NCNP-03 will be calculated using non-compartmental methods.
Time frame: Day 1 (1st dose) for each dose level
Part 2: Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot)
Time frame: Baseline, Week25
Part 2: Change from baseline in skeletal muscle dystrophin protein by mass spectrometry
Time frame: Baseline, Week25
Part 2: Change from baseline in skeletal muscle dystrophin protein levels by immunofluorescence staining
Time frame: Baseline, Week25
Part 2: Change from baseline in percentage of exon 50-skipped mRNA of skeletal muscle dystrophin
Time frame: Baseline, Week25
Part 2: North Star Ambulatory Assessment (NSAA) score
The NSAA is a functional scale devised for use in ambulant children with Duchenne muscular dystrophy (DMD). It consists of 17 activities graded 0 (unable to perform), 1 (performs with modifications), 2 (normal movement). It assesses abilities necessary to remain ambulant that have been found to progressively deteriorate in untreated DMD patients, as well as in other muscular dystrophies such as Becker Muscular Dystrophy. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.
Time frame: Baseline, Week13, Week25
Part 2: Time to Stand (TTSTAND)
Time frame: Baseline, Week13, Week25
Part 2: Time to Run/Walk 10 Meters (TTRW)
Time frame: Baseline, Week13, Week25
Part 2: Time to Climb 4 Stairs (TTCLIMB)
Time frame: Baseline, Week13, Week25
Part 2: Total distance of 6 Minute Walk Test (6MWT)
Time frame: Baseline, Week13, Week25
Part 2: Muscle strength measured by Quantitative Muscle Testing (QMT)
Time frame: Baseline, Week13, Week25
Part 2: Grip/Pinch Strength
Time frame: Baseline, Week13, Week25
Part 2: Performance of Upper Limb (PUL) 2.0. score
The PUL 2.0 provides both a total score and sub-scores for the 3 domains (shoulder, middle, and distal) that in DMD are progressively involved with a proximal to distal gradient. The PUL includes 22 items with an entry item to define the starting functional level. The 22 items are subdivided into the high level shoulder dimension (6 items), middle level elbow dimension (9 items), and distal wrist and hand dimension (7 items). For weaker patients, a low score on the entry item (0 2) means high level items do not need to be performed. Scoring options vary across the scale between 0-1 and 0-2 according to performance. Each dimension can be scored separately with a maximum score of 12 for the high level shoulder dimension, 17 for the middle level elbow dimension, and 13 for the distal wrist and hand dimension. A total score can be achieved by adding the 3 level scores (maximum total score of 42).
Time frame: Baseline, Week13, Week25
Started Sep 2024 (actual). Primary completion is estimated for Mar 2028, 42 months after the start.
Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 42 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →
NS Pharma, Inc.